MINIRIN 15 tablets (DDAVP)0.1 Mg

USD $23.41

Each Minirin contains .1 mg Desmopressin 15 tablets. Treats diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, and high blood urea levels.

ATC Classification: H01BA02
Active Ingrediant: Desmopressin
Generic Name: MINIRIN
Manufacturer: FERRING
Strength: 0.1 Mg
Dosage Type: Tablet
Packaging Type: Bottle in Box
Contains: 15 Tabs

Examples of Packages sent

Desmopressin Information


des moe PRES in


What is this drug used for?

– It is used to help prevent bedwetting.

– It is used to treat a health problem called nocturnal polyuria that causes you to have to wake up at night to pass urine.

– It is used to treat diabetes insipidus.

– It is used to treat hemophilia.

– It is used to treat von Willebrand disease.

– It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

– Flushing

– Dry mouth

– Abdominal cramps

– Stuffy nose

– Runny nose

– Common cold symptoms

– Back pain

– Cough

– Nosebleed

– Sore throat

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

– Low sodium like headache, difficulty focusing, trouble with memory, confusion, weakness, seizures, or change in balance.

– Severe cerebrovascular disease like change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes.

– DVT like edema, warmth, numbness, change in color, or pain in the extremities.

– Nausea

– Vomiting

– Sensing things that seem real but are not

– Loss of strength and energy

– Agitation

– Muscle weakness

– Muscle spasms

– Excessive weight gain

– Lack of appetite

– Shortness of breath

– Severe headache

– Severe dizziness

– Passing out

– Vision changes

– Swelling of arms or legs

– Chest pain

– Coughing up blood

– Fast heartbeat

– Abnormal heartbeat

– Injection site pain, edema, or irritation

– Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.


Medication Safety Issues

Sound-alike/look-alike issues:

Desmopressin may be confused with vasopressin

Geriatric Patients: High-Risk Medication:

Beers Criteria: Desmopressin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older for the treatment of nocturia or nocturnal polyuria due to its high risk of causing hyponatremia; safer alternatives exist (Beers Criteria [AGS 2019]).


Storage and Stability


Nasal spray: Store at 20?C to 25?C (68?F to 77?F). Keep nasal spray in upright position.

Rhinal Tube solution: Store at 2?C to 8?C (36?F to 46?F). May store at 20?C to 25?C (68?F to 77?F) for up to 3 weeks.

Solution for injection: Store at 2?C to 8?C (36?F to 46?F).

Tablet: Store at 20?C to 25?C (68?F to 77?F). Avoid excessive heat. Protect from light.

DDAVP Melt [Canadian product]: Store at 15?C to 25?C (59?F to 77?F) in original container. Protect from moisture.

Nocdurna: Store at 20?C to 25?C (68?F to 77?F). Excursions permitted to 15?C to 30?C (59?F to 86?F). Protect from moisture and light.

Noctiva: Store at 2?C to 8?C (36?F to 46?F); excursions permitted between 0?C and 15?C (32?F and 59?F). Keep nasal spray in upright position. After opening, store at 20?C to 25?C (68?F to 77?F). Discard 60 days after opening.

Octostim [Canadian product]:

Nasal spray: Store at 15?C to 25?C (59?F to 77?F). Store in upright position. Do not freeze.

Solution for injection: Store at 2?C to 8?C (36?F to 46?F). Do not freeze. Following dilution in NS may store at room temperature for up to 24 hours.

Stimate nasal spray: Store at room temperature not to exceed 25?C (77?F). Discard 6 months after opening bottle. Store bottle in upright position.


Adverse Reactions

Cardiovascular: Decreased blood pressure, facial flushing, hypertension

Central nervous system: Chills, dizziness, headache, nostril pain

Endocrine & metabolic: Hyponatremia

Gastrointestinal: Abdominal cramps, abdominal pain, gastrointestinal disease, nausea, sore throat

Hepatic: Increased serum transaminases (transient; associated primarily with tablets)

Local: Burning sensation at injection site, erythema at injection site, swelling at injection site

Neuromuscular & skeletal: Back pain, weakness

Ophthalmic: Abnormal lacrimation, conjunctivitis, ocular edema

Respiratory: Bronchitis, cough, epistaxis, nasal congestion, nasal discomfort, nasopharyngitis, rhinitis, sneezing, upper respiratory tract infection

Rare but important or life-threatening: Abnormality in thinking, agitation, anaphylaxis (rare), balanitis, cerebral thrombosis (acute), chest pain, diarrhea, drowsiness, dyspepsia, edema, eye pruritus, hypersensitivity reaction (rare), insomnia, localized warm feeling, myocardial infarction, pain, palpitations, photophobia, tachycardia, vomiting, vulvar pain, water intoxication, weight gain (edema)

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,


Dosage Type

Packaging Type




There are no reviews yet.

Be the first to review “MINIRIN 15 tablets (DDAVP)0.1 Mg”

Your email address will not be published. Required fields are marked *